PMID- 16405437
OWN - NLM
STAT- MEDLINE
DCOM- 20060328
LR  - 20061115
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 76
IP  - 2
DP  - 2006 Feb
TI  - Effects of IgG and its F(ab')2 fragments of some patients with idiopathic 
      thrombocytopenic purpura on platelet aggregation.
PG  - 153-9
AB  - OBJECTIVES: To make humanized monoclonal antibodies by phage surface display 
      technology, we screened out the specific anti-platelet glycoproteins (GPs) IgG 
      antibody from patients with chronic idiopathic thrombocytopenic purpura (ITP), 
      which can inhibit platelet aggregation. METHODS: We studied plasmas from 68 
      patients with ITP for the presence of IgG antibodies specific for GPIIb/IIIa 
      and/or GPIb/IX using modified monoclonal antibody immobilization of platelet 
      antigen assays. The IgG antibody and its F(ab')(2) fragments of the positive 
      plasmas which could inhibit platelet aggregation function were prepared and 
      purified. Their immunoreactivity to platelet GPs and effects on platelet function 
      were further analyzed. RESULTS: GPIIb/IIIa- and GPIb/IX-specific antibodies were 
      found in 21 and 19 patients, respectively. Six of them had antibodies against 
      both GP complexes. Among the 34 positive plasmas, four with positive 
      anti-GPIIb/IIIa autoantibody showed significant inhibition of platelet 
      aggregation induced by adenosine diphosphate (ADP), whereas one with 
      GPIb/IX-specific antibody inhibited ristocetin-induced platelet aggregation. The 
      purified IgG and its F(ab')(2) fragments from two patients not only retained the 
      ability to bind to platelet GPs but also impaired the in vitro ADP-induced 
      platelet aggregation. CONCLUSIONS: F(ab')(2) portion of the IgG is a functional 
      fragment, which is responsible for the autoantibody interaction with platelet GPs 
      in ITP, and some of them also affect platelet function, which can be used to 
      develop completely humanized anti-GPIIb/IIIa small molecular phage antibody.
FAU - Chu, Xiao Xia
AU  - Chu XX
AD  - Hematology Oncology Center, Qilu Hospital of Shandong University, Jinan, 
      Shandong, China.
FAU - Hou, Ming
AU  - Hou M
FAU - Peng, Jun
AU  - Peng J
FAU - Zhu, Yuan Yuan
AU  - Zhu YY
FAU - Ji, Xue Bin
AU  - Ji XB
FAU - Wang, Lin
AU  - Wang L
FAU - Zhang, Feng
AU  - Zhang F
FAU - Ma, Dao Xin
AU  - Ma DX
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Platelet Membrane Glycoproteins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Chronic Disease
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments/pharmacology/*therapeutic use
MH  - Immunoglobulin G/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation/*drug effects
MH  - Platelet Membrane Glycoproteins/metabolism
MH  - Purpura, Thrombocytopenic, Idiopathic/*drug therapy
EDAT- 2006/01/13 09:00
MHDA- 2006/03/29 09:00
CRDT- 2006/01/13 09:00
PHST- 2006/01/13 09:00 [pubmed]
PHST- 2006/03/29 09:00 [medline]
PHST- 2006/01/13 09:00 [entrez]
AID - EJH557 [pii]
AID - 10.1111/j.1600-0609.2005.00557.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2006 Feb;76(2):153-9. doi: 10.1111/j.1600-0609.2005.00557.x.